In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: Results from a prospective phase II study [3]

Bone Marrow Transplantation

Volumn 35, Issue 10, 2005, Pages 1025-1026

  Bonifazi, F ^a   Bandini, G ^a   Stanzani, M ^a   Palandri, F ^a   Giannini, B ^a   Arpinati, M ^a   Rosti, G ^a   Baccarani, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMATINIB; METHOTREXATE; THYMOCYTE ANTIBODY;

ADULT; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE CLASSIFICATION; HUMAN; IN VIVO STUDY; INCIDENCE; LETTER; LEUKEMIA RELAPSE; LOW DRUG DOSE; PATIENT MONITORING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIBLING; T CELL DEPLETION; TREATMENT PLANNING;

ADULT; ANTILYMPHOCYTE SERUM; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LYMPHOCYTE DEPLETION; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES;

EID: 19044374259     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704940     Document Type: Letter

References (10)

1. Elmaagacli AH, Basoglu S, Peceny R et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 2002; 99: 1130-1135.
2. Mohty M, Kuentz M, Michallet M et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long term results of a randomized study. Blood 2002; 100: 3128-3134.
3. Pistillo MP, Tazzari PL, Bonifazi F et al. Detection of a novel specificity (CTLA-4) in ATG/TMG globulin and sera from ATG-treated leukemic patients. Transplantation 2002; 73: 1295-1302.
4. Bacigalupo A, Lamparelli T, Guidi S et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942-2947.
5. Remberger M, Svahn BM, Hentschke P et al. Effect on cytokine-release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haemopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 823-830.
6. Kroger N, Zabelina T, Kruger W et al. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 2002; 29: 683-689.
7. Bonifazi F, Bandini G, Rondelli D et al. Reduced incidence of GVHD with low-dose rabbit ATG in the preparative regimen for unrelated bone marrow transplants in CML. Bone Marrow Transplant 2003; 32: 237-242.
8. Schetelig J, Borhauser M, Kiehl M et al. Reduced intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation - a retrospective analysis. Bone Marrow Transplant 2004; 33: 483-490.
9. Gratwohl A, Baldomero H, Urbano-Ispizua A. Transplantation in chronic myeloid leukemia. Lancet 2002; 359: 712-713.
10. Schleuning M, Gunther W, Tischer J et al. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML. Bone Marrow Transplant 2003; 32: 243-250.